Alyftrek 10-50-125 MG tablet 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FJUV3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,991
Award facts
- Contract value 100% obligated
- $41,990.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $41,990.94 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for supply of ALYFTREK 10-50-125 mg tablets (14-unit packages). The delivery order, issued without set-aside designation, is scheduled for completion by December 15, 2025, and represents one of numerous pharmaceutical supply orders the company has received from DLA's Medical Supply Chain division. DMS Pharmaceutical Group maintains registration in the System for Award Management since July 2001 and operates as a critical supplier within the federal pharmaceutical distribution network, serving Department of Defense healthcare facilities worldwide.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with DLA designated as SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, awarded on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036. The PPV-G GEN V contract encompasses a 30-month base period with three 30-month option periods and positions the company as one of multiple regional prime vendor contractors within DLA's broader $30.3 billion pharmaceutical supply acquisition strategy. The IDC authorizes DLA to issue firm fixed-price delivery orders for a comprehensive range of branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and medical consumables supporting recurring medical supply needs across military healthcare facilities globally.
Quick answers
Who was awarded contract SPE2DR26FJUV3?
SPE2DR26FJUV3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 12, 2025.
How much is contract SPE2DR26FJUV3 worth?
The government has obligated $41,991 on SPE2DR26FJUV3.
Is contract SPE2DR26FJUV3 an order under another contract?
Yes. SPE2DR26FJUV3 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUV3 competed?
The extent of competition for SPE2DR26FJUV3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award